Our projects explore the role of cancer metabolism across a range of in vitro and in vivo models, including leukemia, glioblastoma, lung, breast, colon, cervical, and ovarian cancers. The overarching goal is to identify key metabolic pathways, whose players can serve as biomarkers and targets, paving the way for the development of novel metabolism-based treatments.

An effective cancer therapy must consider the dynamic metabolic reprogramming that cancer cells undergo — not only at the time of diagnosis and initial treatment but also throughout disease progression, follow-up, and recurrence. Tumor relapse is often driven by a subset of cells that survive therapeutic intervention. Reapplying the same treatment regimen can be counterproductive, as it may favor the selection of more resistant and aggressive clones. In this context, cancer metabolism research offers critical insights into pathways associated with drug resistance and cellular dormancy.

Ultimately, through comprehensive studies of both models and tumors, we aim to develop more personalized, disease-specific therapeutic strategies, improving the clinical management and outcomes for cancer patients.